Kairos Pharma, Ltd. (KAPA)Healthcare | Biotechnology | Los Angeles, United States | NYSE American
0.24 USD
0.00
(-1.618%) ⇩
(Aug. 28, 2026, 3:54 p.m.
EDT)
After hours: 0.24 +0.00 (1.181%) ⇧ (Aug. 28, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:09 a.m. EDT
The immediate outlook is severely clouded by a massive disconnect between the market's valuation and the company's operational reality. While analysts project a mean price target of $7.00, implying a 23-fold multiple expansion from current levels, the underlying business is hemorrhaging cash with negative free cash flow and negative operating cash flow. This creates a dangerous 'value trap' scenario where the stock trades at a premium despite having no earnings power and a forward P/E that is mathematically nonsensical due to negative earnings. The recent price action confirms this skepticism; after a brief rally, the stock has drifted lower, closing near its 52-week low, suggesting the market is not buying the hype. Furthermore, the statistical forecasting model predicts a further decline over the next 45 days, reinforcing the bearish technical setup. There is no dividend to provide a floor, and the lack of a multi-year price history prevents any assessment of long-term structural resilience, leaving the investment case entirely dependent on a speculative turnaround that has not yet materialized. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.084212 |
| MSTL | 0.147773 |
| AutoETS | 0.154486 |
| AutoARIMA | 0.169627 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 12.42 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.134 |
| Excess Kurtosis | -0.32 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 5,618,721 |
| Forward P/E | -0.35 |
| Website | https://kairospharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.829078 |
| Address1 | 2,355 Westwood Blvd. |
| Address2 | Suite 139 |
| All Time High | 4.0 |
| All Time Low | 0.22 |
| Ask | 0.2369 |
| Ask Size | 6,800 |
| Average Daily Volume10 Day | 494,850 |
| Average Daily Volume3 Month | 2,244,091 |
| Average Volume | 2,244,091 |
| Average Volume10Days | 494,850 |
| Bid | 0.236 |
| Bid Size | 200 |
| Book Value | 0.196 |
| City | Los Angeles |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.2371 |
| Current Ratio | 11.977 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.249 |
| Day Low | 0.232 |
| Display Name | Kairos Pharma |
| Ebitda | -5,815,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.515 |
| Enterprise Value | 2,992,720 |
| Eps Current Year | -0.37 |
| Eps Forward | -0.67 |
| Eps Trailing Twelve Months | -0.28 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.33932 |
| Fifty Day Average Change | -0.10222 |
| Fifty Day Average Change Percent | -0.30124956 |
| Fifty Two Week Change Percent | -82.9078 |
| Fifty Two Week High | 2.11 |
| Fifty Two Week High Change | -1.8728999 |
| Fifty Two Week High Change Percent | -0.88763034 |
| Fifty Two Week Low | 0.22 |
| Fifty Two Week Low Change | 0.017100006 |
| Fifty Two Week Low Change Percent | 0.0777273 |
| Fifty Two Week Range | 0.22 - 2.11 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,726,493,400,000 |
| Float Shares | 15,704,218 |
| Forward Eps | -0.67 |
| Forward P E | -0.35388058 |
| Free Cashflow | -1,888,125 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 1 |
| Fullday Change | -0.00389999 |
| Fullday Change Percent | -1.61825 |
| Fullday Price | 0.2399 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.33611 |
| Held Percent Institutions | 0.07819 |
| Implied Shares Outstanding | 23,697,683 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company's products under the preclinical stage include KROS 201 that activates T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist designed to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, as well as a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions for the treatment of autoimmune disease; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor that targets tumor cells in RelA/p65 biomarker-positive solid tumors for the treatment of triple-negative breast cancer; KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13, reversing tumor associated macrophage inhibition that blocks the IL4/IL13 cytokine immune receptors for the treatment of triple-negative breast cancer; and ENV 205, an antibody fragment that targets mitochondrial DNA for the treatment of prostate cancer. The company also develops ENV-105 (carotuximab). The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California. |
| Market | us_market |
| Market Cap | 5,618,721 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1832548029 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -5,805,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,711,141 |
| Number Of Analyst Opinions | 2 |
| Open | 0.2436 |
| Operating Cashflow | -3,970,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 310 948 2356 |
| Post Market Change | 0.0027999878 |
| Post Market Change Percent | 1.1809311 |
| Post Market Price | 0.2399 |
| Post Market Time | 1,787,961,571 |
| Previous Close | 0.241 |
| Price Eps Current Year | -0.6408108 |
| Price Hint | 4 |
| Price To Book | 1.2096939 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.909 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.00389999 |
| Regular Market Change Percent | -1.61825 |
| Regular Market Day High | 0.249 |
| Regular Market Day Low | 0.232 |
| Regular Market Day Range | 0.232 - 0.249 |
| Regular Market Open | 0.2436 |
| Regular Market Previous Close | 0.241 |
| Regular Market Price | 0.2371 |
| Regular Market Time | 1,787,946,890 |
| Regular Market Volume | 210,692 |
| Return On Assets | -0.66909 |
| Return On Equity | -1.13958 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 23,697,683 |
| Shares Percent Shares Out | 0.0154 |
| Shares Short | 364,248 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 192,173 |
| Short Name | Kairos Pharma, Ltd. |
| Short Percent Of Float | 0.0216 |
| Short Ratio | 0.07 |
| Source Interval | 15 |
| State | CA |
| Symbol | KAPA |
| Target High Price | 12.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 7.0 |
| Target Median Price | 7.0 |
| Total Cash | 2,626,000 |
| Total Cash Per Share | 0.111 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.28 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.573305 |
| Two Hundred Day Average Change | -0.336205 |
| Two Hundred Day Average Change Percent | -0.58643305 |
| Type Disp | Equity |
| Volume | 210,692 |
| Website | https://kairospharma.com |
| Zip | 90,064 |